ArticleFrontiers in immunology2025
Hepatotoxicity associated with anti-neoplastic agents: a pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System database.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Haematological toxicity associated with antineoplastic drugs: a pharmacovigilance analysis based on the FDA adverse event reporting system database.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatotoxicity is commonly observed in patients undergoing chemotherapy. However, the clinical features and outcomes of hepatotoxicity associated with anti-neoplastic agents remain unclear. In this study, we investigated the characteristics and risk factors of hepatotoxicity associatedwith anti-neoplastic agents. Methods: We conducted a retrospective pharmacovigilance analysis using data acquired from the FDA Adverse Event Reporting System (FAERS) database (Q1-2004 to Q3 2024). Hepatotoxicity risk was assessed by disproportionality analysis, while LASSO and multivariate logistic regression were applied to control for potential confounders. Finally, we analyzed the time duration to the onset of hepatotoxicity. Results: A total of 56 anti-neoplastic agents exhibited positive signals for hepatotoxicity, involving 4,195 reports. Female patients (46.50%) were more frequently affected than males (26.70%), with a median age of 56 years. 627 patients (14.95%) experienced fatal or life-threatening outcomes. The top three drugs with the highest Reporting Odds Ratio (ROR) values were mercaptopurine (ROR = 26.57), pegaspargase (ROR = 13.67) and blinatumomab (ROR = 11.93). Most events occurred within the first month (44.18%) and the median TTO value in the Fatal group (22.5 days) was shorter than that in the non-fatal group (42 days) (p < 0.05). Furthermore, Weibull shape parameter (WSP) analysis indicated that 20 of the top 30 drugs were random failure models. Discussion: This analysis profiles hepatotoxicity signals for anti-neoplastic agents but reveals a major methodological gap: without using a validated causality tool like the updated RUCAM, FAERS data cannot confirm druginduced liver injury (DILI). Future studies should integrate RUCAM to improvespecificity and clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.